Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...
Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback